LivaNova to Present Scientific Data at American Epilepsy Society 2022 Annual Meeting
Retrieved on:
Wednesday, November 30, 2022
Other Health, Research, Managed Care, Mental Health, Medical Devices, Hospitals, Health Technology, Science, Surgery, Biotechnology, Neurology, Health, Real-World Evidence, American Epilepsy Society, Doctor of Philosophy, Epilepsy, Head, Old age, Saint Thomas - Rutherford Hospital, AES, Conference, LivaNova, Poster, Safety, New product development, Master of Science, Vagus nerve, Annual report, Annual general meeting, Senior, News, LIVN, PLC, Anticonvulsant, PD, Risk, Quality of life, Hope, DRE, Pharmaceutical industry, Communications satellite, Health insurance, Patient
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, today announced its participation in the American Epilepsy Society (AES) 2022 Annual Meeting, taking place December 2-6 in Nashville, Tennessee.
Key Points:
- LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, today announced its participation in the American Epilepsy Society (AES) 2022 Annual Meeting, taking place December 2-6 in Nashville, Tennessee.
- The Companys therapies and technologies will be featured in seven scientific posters aimed at engaging clinical collaborators and deepening understanding for the treatment of drug-resistant epilepsy.
- The scientific poster presentations feature the work of LivaNova employees and/or independent investigators.
- Conference attendees will have an opportunity to view these poster presentations and pose questions to presenters at the conference.